Vox sanguinis · 2006
Detection of a new weak A blood-group allele (Aw11).
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pruss A, Heymann G A, Braun J, Kiesewetter H H, Salama A
Аннотация
BACKGROUND AND OBJECTIVES: Weak ABO variants may escape tests using unlicensed sera.
MATERIALS AND METHODS: Prior to transfusion, ABO grouping was performed using an automated system and in-house diluted sera, and manual and bedside test techniques. Genotyping and sequencing were performed using standard methods.
RESULTS: Initially, the red blood cells (RBC) of the first-time blood donor were typed as B, but pretransfusion testing carried out using the bedside test indicated the presence of an additional A phenotype. Serological re-examination confirmed the bedside test results, and the allele in question was identified, by genotyping, as a new weak A variant (Aw11).
CONCLUSIONS: The use of CE-marked and licensed antisera is recommended to avoid ABO mistyping.
MATERIALS AND METHODS: Prior to transfusion, ABO grouping was performed using an automated system and in-house diluted sera, and manual and bedside test techniques. Genotyping and sequencing were performed using standard methods.
RESULTS: Initially, the red blood cells (RBC) of the first-time blood donor were typed as B, but pretransfusion testing carried out using the bedside test indicated the presence of an additional A phenotype. Serological re-examination confirmed the bedside test results, and the allele in question was identified, by genotyping, as a new weak A variant (Aw11).
CONCLUSIONS: The use of CE-marked and licensed antisera is recommended to avoid ABO mistyping.